Opioid Abuse Clinical Trial
— BINDeR-TXOfficial title:
Buprenorphine Induction and Naloxone Distribution Program-Combined With Warm Hand-Off Referral to Continued Treatment
NCT number | NCT06087991 |
Other study ID # | 158724 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | April 1, 2023 |
Est. completion date | October 1, 2024 |
This study is a collaboration between the University of Utah and Castleview Hospital in Price, Utah. Buprenorphine is a medication approved by the FDA to treat Opioid Use Disorder (OUD). Castleview Hospital currently does not prescribe buprenorphine in the emergency department (ED) instead it refers patients to outside addiction treatment facilities. This is a service focused project which the University of Utah will provide mentoring and education to Castleview in implementing an in ED buprenorphine/naloxone distribution program along with referral to continued services. After the program has been implemented, the investigators will evaluate it using quantitative surveys of program participants and qualitative interviews of hospital staff and stakeholders.
Status | Recruiting |
Enrollment | 362 |
Est. completion date | October 1, 2024 |
Est. primary completion date | October 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: For qualitative interviews with providers, administrators, stakeholders: - Must be affiliated with Castleview Hospital as a provider, administrator or stakeholder. For the quantitative surveys: - Must be a Castleview Hospital patient who receives the BINDeR-Tx model. Exclusion Criteria: For qualitative interviews with providers, administrators, stakeholders: - Not familiar with the BINDeR-Tx model - No interaction with the BINDeR-Tx model For the quantitative surveys: - Unable to speak and read English - Subject is unable to provide contact information |
Country | Name | City | State |
---|---|---|---|
United States | University of Utah | Salt Lake City | Utah |
Lead Sponsor | Collaborator |
---|---|
Jerry Cochran |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patient Focused: Number of patients receiving services. | Will be the aggregate number of individuals who received ED-initiated buprenorphine. | 24 months | |
Secondary | Implementation and service quality: Satisfaction with projected service | Qualitative interviews including clinicians, hospital staff, and community members associated with Castleview Hospital will be the investigators using the Consolidated Framework for Implementation Research (CFIR). | 24 months. | |
Secondary | Implementation and service quality: Patient satisfaction | Patient satisfaction will be assessed using the Patient Satisfaction Questionnaire Short Form (PSQ-18) | enrollment and 6 months post enrollment | |
Secondary | Substance use diagnosis and treatment | Using the Government Performance and Results Act (GPRA) Outcome questions on substance use within the past 30 days, other substance use disorder diagnoses and treatment in the past 30 days, and mental health diagnoses. | enrollment and 6 months post enrollment | |
Secondary | Social Connectedness | Social connectedness will be measured using the GPRA questions on mutual support group attendance in the last 30 days and relationship satisfaction and support. | enrollment and 6 months post enrollment | |
Secondary | Living Conditions | Living conditions will be measured using the GPRA questions on residence within the past 30 days. | enrollment and 6 months post enrollment | |
Secondary | Mental and Physical Health Problems and Treatment/Recovery | Mental and physical health problems and treatment/recovery will be measured using the GPRA questions on mental health symptoms and medical care received in the past 30 days and insurance status. | enrollment and 6 months post enrollment | |
Secondary | Legal Status | Legal status will be measured using the GPRA questions on incarceration in the past 30 days, charges, trial, sentencing, parole, probation, and drug court status. | enrollment and 6 months post enrollment | |
Secondary | Discharge status | Discharge status will be measured using the GRPA questions on substance use diagnosis and treatment in the past 30 days. | enrollment and 6 months post enrollment | |
Secondary | Follow-up Status | Follow-up status will be measured using the GPRA questions on contact and follow-up status. | enrollment and 6 months post enrollment | |
Secondary | Education, Employment, and Income | Education, employment, and income will be measured using the GPRA questions on education level, employment status, living expenses and income status. | enrollment and 6 months post enrollment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04839978 -
Community Trial in the Cherokee Nation
|
N/A | |
Completed |
NCT05593341 -
Opioid Education in Total Knee Arthroplasty
|
N/A | |
Terminated |
NCT04495374 -
Oral Pregabalin as Preemptive Analgesia in Abdominal Hysterectomy
|
Phase 4 | |
Terminated |
NCT03822962 -
Pain Management Following Sinus Surgery
|
Early Phase 1 | |
Completed |
NCT03936985 -
Validation of a Community Pharmacy-Based Prescription Drug Monitoring Program Risk Screening Tool
|
||
Active, not recruiting |
NCT01740414 -
Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers
|
Phase 2 | |
Completed |
NCT00499746 -
The Discriminative Effects of Tramadol in Humans
|
Phase 1/Phase 2 | |
Completed |
NCT03684681 -
The Navigator Trial
|
N/A | |
Completed |
NCT04340622 -
Efficacy And Safety Of An Innovative Treatment Of Opiate Use Disorders
|
N/A | |
Completed |
NCT04018664 -
Oral Abuse Potential Study of Nalbuphine
|
Phase 1 | |
Completed |
NCT00699010 -
Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse
|
Phase 2 | |
Recruiting |
NCT05006079 -
Opioid/Benzodiazepine Polydrug Abuse: Aim 3
|
Phase 2 | |
Completed |
NCT04710069 -
Postoperative Opt-In Narcotic Treatment Study
|
N/A | |
Terminated |
NCT03992079 -
A Multimodal Enhanced Recovery Program in Anorectal Surgery
|
N/A | |
Active, not recruiting |
NCT03570099 -
Naloxone Treatment in Skåne County - Effect on Drug-related Mortality and Overdose-related Complications
|
||
Completed |
NCT02804152 -
Program for Pain & Prescription Opioid Use in Pregnancy
|
N/A | |
Active, not recruiting |
NCT01632982 -
Mobile Psychosocial Interventions for MMT Clients
|
N/A | |
Active, not recruiting |
NCT01136356 -
A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05706311 -
Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool
|
N/A | |
Completed |
NCT03743493 -
PCORnet Opioid Surveillance Study
|